Mapping the genes for haloperidol-induced catalepsy

Stephen Kanes, Katherine Dains, Laura Cipp, John Gatley, Barbara Hitzemann, Erik Rasmussen, Scott Sanderson, Marni Silverman, Robert Hitzemann

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The strain means for haloperidol-induced catalepsy were determined in the 26 strain BXD recombinant inbred series. The ED50 values ranged from 0.55 mg/kg (strain 30) to 7.9 mg/kg (strain 2). Heritability for the catalepsy response was 0.78 and the number of effective loci was estimated to be four. The strain means were correlated with the strain distribution patterns for 1300 marker loci of known chromosomal location and polymorphic between the C57BL/6J and DBA/2J strains. Six quantitative trait loci (QTLs) were identified at P <.01. Two of the six QTLs were confirmed in a sample of B6XD2 F2 animals (n = 144), phenotyped for haloperidol response and genotyped for microsatellites closely linked to the QTLs. The confirmed QTL on chromosome 4 is near the b locus. The confirmed QTL on chromosome 9 is closely linked to Drd2, the D2 dopamine receptor gene. One hundred of the F2 individuals were phenotyped for D2 dopamine receptor binding using the ligand [125I]epidepride as the ligand. Consistent with previous results, the nonresponsive F2 individuals showed modestly higher receptor binding in all brain regions examined: the nucleus accumbens core, the nucleus accumbens shell, the lateral caudate putamen, the dorsomedial caudate putamen, the substantia nigra zona compacta and the ventral tegmental area. The DBA/2J allele of the chromosome 9 QTL was associated with higher receptor binding in all brain areas except the ventral tegmental area. Overall, the data illustrate that either near or part of Drd2 is a QTL which has significant effects on both haloperidol response and D2 dopamine receptor binding. However, the data also illustrate that most of the genetic variance in either haloperidol response or D2 dopamine receptor binding is not associated with Drd2.

Original languageEnglish (US)
Pages (from-to)1016-1025
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume277
Issue number2
StatePublished - May 1996
Externally publishedYes

Fingerprint

Catalepsy
Chromosome Mapping
Quantitative Trait Loci
Haloperidol
Dopamine D2 Receptors
Chromosomes, Human, Pair 9
Ventral Tegmental Area
Putamen
Nucleus Accumbens
Ligands
Chromosomes, Human, Pair 4
Herpes Zoster
Brain
Microsatellite Repeats
Alleles

ASJC Scopus subject areas

  • Pharmacology

Cite this

Kanes, S., Dains, K., Cipp, L., Gatley, J., Hitzemann, B., Rasmussen, E., ... Hitzemann, R. (1996). Mapping the genes for haloperidol-induced catalepsy. Journal of Pharmacology and Experimental Therapeutics, 277(2), 1016-1025.

Mapping the genes for haloperidol-induced catalepsy. / Kanes, Stephen; Dains, Katherine; Cipp, Laura; Gatley, John; Hitzemann, Barbara; Rasmussen, Erik; Sanderson, Scott; Silverman, Marni; Hitzemann, Robert.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 277, No. 2, 05.1996, p. 1016-1025.

Research output: Contribution to journalArticle

Kanes, S, Dains, K, Cipp, L, Gatley, J, Hitzemann, B, Rasmussen, E, Sanderson, S, Silverman, M & Hitzemann, R 1996, 'Mapping the genes for haloperidol-induced catalepsy', Journal of Pharmacology and Experimental Therapeutics, vol. 277, no. 2, pp. 1016-1025.
Kanes S, Dains K, Cipp L, Gatley J, Hitzemann B, Rasmussen E et al. Mapping the genes for haloperidol-induced catalepsy. Journal of Pharmacology and Experimental Therapeutics. 1996 May;277(2):1016-1025.
Kanes, Stephen ; Dains, Katherine ; Cipp, Laura ; Gatley, John ; Hitzemann, Barbara ; Rasmussen, Erik ; Sanderson, Scott ; Silverman, Marni ; Hitzemann, Robert. / Mapping the genes for haloperidol-induced catalepsy. In: Journal of Pharmacology and Experimental Therapeutics. 1996 ; Vol. 277, No. 2. pp. 1016-1025.
@article{536145c983b746d0b5008e605a3f9a3e,
title = "Mapping the genes for haloperidol-induced catalepsy",
abstract = "The strain means for haloperidol-induced catalepsy were determined in the 26 strain BXD recombinant inbred series. The ED50 values ranged from 0.55 mg/kg (strain 30) to 7.9 mg/kg (strain 2). Heritability for the catalepsy response was 0.78 and the number of effective loci was estimated to be four. The strain means were correlated with the strain distribution patterns for 1300 marker loci of known chromosomal location and polymorphic between the C57BL/6J and DBA/2J strains. Six quantitative trait loci (QTLs) were identified at P <.01. Two of the six QTLs were confirmed in a sample of B6XD2 F2 animals (n = 144), phenotyped for haloperidol response and genotyped for microsatellites closely linked to the QTLs. The confirmed QTL on chromosome 4 is near the b locus. The confirmed QTL on chromosome 9 is closely linked to Drd2, the D2 dopamine receptor gene. One hundred of the F2 individuals were phenotyped for D2 dopamine receptor binding using the ligand [125I]epidepride as the ligand. Consistent with previous results, the nonresponsive F2 individuals showed modestly higher receptor binding in all brain regions examined: the nucleus accumbens core, the nucleus accumbens shell, the lateral caudate putamen, the dorsomedial caudate putamen, the substantia nigra zona compacta and the ventral tegmental area. The DBA/2J allele of the chromosome 9 QTL was associated with higher receptor binding in all brain areas except the ventral tegmental area. Overall, the data illustrate that either near or part of Drd2 is a QTL which has significant effects on both haloperidol response and D2 dopamine receptor binding. However, the data also illustrate that most of the genetic variance in either haloperidol response or D2 dopamine receptor binding is not associated with Drd2.",
author = "Stephen Kanes and Katherine Dains and Laura Cipp and John Gatley and Barbara Hitzemann and Erik Rasmussen and Scott Sanderson and Marni Silverman and Robert Hitzemann",
year = "1996",
month = "5",
language = "English (US)",
volume = "277",
pages = "1016--1025",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Mapping the genes for haloperidol-induced catalepsy

AU - Kanes, Stephen

AU - Dains, Katherine

AU - Cipp, Laura

AU - Gatley, John

AU - Hitzemann, Barbara

AU - Rasmussen, Erik

AU - Sanderson, Scott

AU - Silverman, Marni

AU - Hitzemann, Robert

PY - 1996/5

Y1 - 1996/5

N2 - The strain means for haloperidol-induced catalepsy were determined in the 26 strain BXD recombinant inbred series. The ED50 values ranged from 0.55 mg/kg (strain 30) to 7.9 mg/kg (strain 2). Heritability for the catalepsy response was 0.78 and the number of effective loci was estimated to be four. The strain means were correlated with the strain distribution patterns for 1300 marker loci of known chromosomal location and polymorphic between the C57BL/6J and DBA/2J strains. Six quantitative trait loci (QTLs) were identified at P <.01. Two of the six QTLs were confirmed in a sample of B6XD2 F2 animals (n = 144), phenotyped for haloperidol response and genotyped for microsatellites closely linked to the QTLs. The confirmed QTL on chromosome 4 is near the b locus. The confirmed QTL on chromosome 9 is closely linked to Drd2, the D2 dopamine receptor gene. One hundred of the F2 individuals were phenotyped for D2 dopamine receptor binding using the ligand [125I]epidepride as the ligand. Consistent with previous results, the nonresponsive F2 individuals showed modestly higher receptor binding in all brain regions examined: the nucleus accumbens core, the nucleus accumbens shell, the lateral caudate putamen, the dorsomedial caudate putamen, the substantia nigra zona compacta and the ventral tegmental area. The DBA/2J allele of the chromosome 9 QTL was associated with higher receptor binding in all brain areas except the ventral tegmental area. Overall, the data illustrate that either near or part of Drd2 is a QTL which has significant effects on both haloperidol response and D2 dopamine receptor binding. However, the data also illustrate that most of the genetic variance in either haloperidol response or D2 dopamine receptor binding is not associated with Drd2.

AB - The strain means for haloperidol-induced catalepsy were determined in the 26 strain BXD recombinant inbred series. The ED50 values ranged from 0.55 mg/kg (strain 30) to 7.9 mg/kg (strain 2). Heritability for the catalepsy response was 0.78 and the number of effective loci was estimated to be four. The strain means were correlated with the strain distribution patterns for 1300 marker loci of known chromosomal location and polymorphic between the C57BL/6J and DBA/2J strains. Six quantitative trait loci (QTLs) were identified at P <.01. Two of the six QTLs were confirmed in a sample of B6XD2 F2 animals (n = 144), phenotyped for haloperidol response and genotyped for microsatellites closely linked to the QTLs. The confirmed QTL on chromosome 4 is near the b locus. The confirmed QTL on chromosome 9 is closely linked to Drd2, the D2 dopamine receptor gene. One hundred of the F2 individuals were phenotyped for D2 dopamine receptor binding using the ligand [125I]epidepride as the ligand. Consistent with previous results, the nonresponsive F2 individuals showed modestly higher receptor binding in all brain regions examined: the nucleus accumbens core, the nucleus accumbens shell, the lateral caudate putamen, the dorsomedial caudate putamen, the substantia nigra zona compacta and the ventral tegmental area. The DBA/2J allele of the chromosome 9 QTL was associated with higher receptor binding in all brain areas except the ventral tegmental area. Overall, the data illustrate that either near or part of Drd2 is a QTL which has significant effects on both haloperidol response and D2 dopamine receptor binding. However, the data also illustrate that most of the genetic variance in either haloperidol response or D2 dopamine receptor binding is not associated with Drd2.

UR - http://www.scopus.com/inward/record.url?scp=0030424509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030424509&partnerID=8YFLogxK

M3 - Article

VL - 277

SP - 1016

EP - 1025

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -